Cure JM Research Grants - Request for Proposals

The Cure JM Foundation (Cure JM) announces its Request for Proposals for 2023 for advancing research to improve medical treatment and work toward a cure for Juvenile Myositis.

Cure JM is a 501(c)(3) non-profit organization established in 2003. The mission of Cure JM is to find better treatments and a cure for Juvenile Myositis and improve the lives of families affected by JM. Approximately 2 to 4 children in a million in the United States are diagnosed with JM each year.

In 2023, Cure JM has committed to funding new research grants up to $75K/year for up to 2 years with a preference for individuals who have at least 25% protected research time from their institution.

Grant Application Process

Proposals should be submitted electronically as one single PDF file to andrew.heaton@curejm.org and must be received by the submission deadline for applications stated in the research announcement timeline. (See Grant Application for specific information.)

Timeline

- Request for Proposals Begins: May 30, 2023
- Application Deadline: July 30th, 2023
- Review of Submitted Applications Completed: September, 2023
- Anticipated Date for Notification of Awards: October, 2023
- Anticipated Funding Start Date: November 1, 2023

The proposal is up to 4 pages long maximum, and the following are also required but do NOT count toward page limits:

- A lay summary no longer than one page written at the 8th-grade reading level
- A curriculum vitae/biosketch in NIH format
- A letter of support is required from either a division head/department chair/supervisor at your institution
- A letter of collaboration submitted by each and all investigators involved in the grant proposal
- If samples (blood, muscle, skin, etc.) are to be studied and they were not obtained with IRB-approved informed consent by the PI, then a letter of collaboration is needed from the investigator as to who did obtain those samples, citing the IRB #
Eligibility

Applicants must hold a Ph. D. or M.D. degree or equivalent and work in an accredited medical school, university, hospital, or research institute, which must agree to supply the clinical and/or laboratory facilities. The foundation strongly encourages collaborations from two or more institutions that bring together a spectrum of expertise. Grant applications are called for across programs relating to all aspects of; basic research, clinical trials, translational studies, diagnosis, and clinical care of juvenile myositis. A pertinent but not exhaustive list of priorities includes:

- Conducting analyses on samples and/or data available from innovative treatment clinical studies.
- Collaboration with pharmaceutical companies or other research organizations that are developing new therapies that may have utility in the treatment of juvenile myositis. The collaboration may comprise the generation of clinical protocols for new treatments and a defined route to funding a clinical study. Such proposals should include solid evidence of access to the therapy being proposed for investigation.
- Clinical protocols for repurposed drugs for the treatment of juvenile myositis. Such proposals should include solid evidence of access to the therapy being proposed for investigation and a defined route to funding a clinical study.
- Investigations of in vitro or in vivo models of juvenile myositis with the objective of the development of new therapies.
- Novel diagnostic strategies, including the development of biomarkers.
- All aspects of clinical care, spanning mental health and consensus treatment protocols.

Grants Review

Research proposals are reviewed by selected members of the Cure JM Scientific Review Committee utilizing the NIH Grant Application Scoring System. The proposal scores, along with feedback from the reviewers, will be shared with the Cure JM Research Committee for evaluation. The Research committee will make recommendations for funding to the Cure JM Board for a final funding decision. Applicants will be notified by the Cure JM Chief Scientific Officer when a decision is made.

Reports and Payments

Annual or semi-annual progress reports are required to be submitted by the Principal Investigator and shall be due no later than 30 days after a reporting schedule to be detailed in the grant agreement. A Final Report, including a full financial report and progress report, is required within 60 days after the end of the grant period. Both annual and final reports are required to include an expenditure report detailing how the award has been spent. A layperson summary (200-300 words) of major accomplishments and relevance to JM patients shall accompany each Progress report and the final report. Award payments will be made at the beginning of the project year and at 12 months after receipt of the annual progress report.

Budget
A detailed budget should provide itemized detail for each major category of the budget report included in the application. The award does not provide for indirect costs. Award funding may be used for salary support, consumable supplies, equipment, travel (< $1500), and other items necessary to conduct the proposed research.

**Data Sharing**

All successful grantees are encouraged to share data. The CureJM Foundation does not anticipate that researchers will share all scientific data generated in a study. Grantees should indicate which scientific data will be shared based on ethical, legal, and technical factors and provide the rationale for these decisions. The foundation encourages researchers to make scientific data available for as long as they anticipate it being useful for the larger research community, institutions, and/or the broader public.

**Proprietary Information**

All Cure JM-funded proposals must contain a layperson abstract for Cure JM’s use in press releases. Cure JM Foundation must be acknowledged in all dissemination materials (e.g. publications, scientific exhibits, scientific presentations, press releases, etc.) related to research supported in full or in part using this grant, and one copy of any published reports must be sent to Cure JM within 30 days of final production.

A stipulation of award acceptance is to present research outcomes, upon invitation, at either a virtual or in-person Cure JM medical conference and/or Cure JM annual family conference following receipt of the award. Due to COVID-19 considerations, should Cure JM be unable to hold its family conference, award recipients agree to present research outcomes virtually at a Cure JM Town Hall webinar.

This information also appears at [http://www.curejm.org/research/funding.php](http://www.curejm.org/research/funding.php)